Literature DB >> 14670341

Epidemiology of tuberculosis and leprosy, Sabah, Malaysia.

Jiloris F Dony1, Jamaliah Ahmad, Yap Khen Tiong.   

Abstract

The objectives in this epidemiology review are to measure and report the extent of morbidity and mortality due to tuberculosis (TB), the proportion of new sputum smear positive cases in districts and the status of cohort analysis as of 1999. As for leprosy, the main objective is to determine morbidity and the treatment outcomes of Multiple Drug Therapy (MDT). Based on the results obtained, a comprehensive action plan for prevention, control and monitoring of tuberculosis and leprosy cases and patients is being produced and implemented throughout the state. The analysis concentrated on patients diagnosed at all out-patient units and admitted in all of the state's hospitals. The patient particulars were recorded using a standardized format based on TB and Leprosy Health Management Information System (TB HMIS). TB was the second highest by notification of communicable diseases in Malaysia in 2001. 29% or about one-third of the national TB cases are from Sabah. However, it has been noted that there was an average decline of 2.6% in annual notification since 10 years ago to date. There was also a reduction of 11.4% in 2001 as compared to annual notification in 2000. Immigrants contribute more than 24% in detection of new cases since 1990. Treatment success rate in term of completion of treatment to date is 82%. Mortality rate has steadily declined from 14 deaths to 7 deaths per 100,000 population. Leprosy in Sabah also contributes to 30% of the yearly total caseload of Malaysia and has the highest notification rate of 2 per every 100,000 population as compared to other states. The average registered leprosy cases over the past 5 years are 239 cases and the prevalence rate is 0.7/10,000 population. The state has successfully achieved its goal to decrease leprosy as per the World Health Organization (WHO) goal of yearly overall prevalence rate of less than 1 case for every 10,000 population. However, the districts of Kudat, Tawau, Lahad Datu, Kota Kinabalu and Semporna are still within the prevalence rate of more than one per 10,000 population. This review highlights some interesting findings which can be incorporated into the State and Districts action plans and strategies. It is also noted that in order to translate National Plans and Strategies into effective action at the community level, health workers need relevant up-to-date knowledge of the pattern of health and disease, and of their determinants, in each district. The Sabah Health Department continues to organize and support programs related to management and control of tuberculosis and leprosy to progressively reduce the incidence of these diseases in the community by breaking the chain of transmission of Mycobacterium tuberculosis and M. leprae, respectively.

Entities:  

Mesh:

Year:  2004        PMID: 14670341     DOI: 10.1016/j.tube.2003.08.002

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  9 in total

1.  Understanding tuberculosis: perspectives and experiences of the people of Sabah, East Malaysia.

Authors:  Christina Rundi
Journal:  J Health Popul Nutr       Date:  2010-04       Impact factor: 2.000

2.  A prospective study of tuberculosis drug susceptibility in sabah, malaysia, and an algorithm for management of isoniazid resistance.

Authors:  Muhammad Redzwan S Rashid Ali; Uma Parameswaran; Timothy William; Elspeth Bird; Christopher S Wilkes; Wai Khew Lee; Tsin Wen Yeo; Nicholas M Anstey; Anna P Ralph
Journal:  J Trop Med       Date:  2015-03-09

3.  Pulmonary tuberculosis in outpatients in Sabah, Malaysia: advanced disease but low incidence of HIV co-infection.

Authors:  Timothy William; Uma Parameswaran; Wai Khew Lee; Tsin Wen Yeo; Nicholas M Anstey; Anna P Ralph
Journal:  BMC Infect Dis       Date:  2015-01-31       Impact factor: 3.090

4.  Treating More with Less: Effectiveness and Event Outcomes of Antituberculosis Fixed-dose Combination Drug versus Separate-drug Formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for Pulmonary Tuberculosis Patients in Real-world Clinical Practice.

Authors:  Jacqueline Mui Lan Lai; Su Lan Yang; Richard Avoi
Journal:  J Glob Infect Dis       Date:  2019 Jan-Mar

Review 5.  Developing an evidence assessment framework and appraising the academic literature on migrant health in Malaysia: a scoping review.

Authors:  Allard Willem de Smalen; Zhie X Chan; Claudia Abreu Lopes; Michaella Vanore; Tharani Loganathan; Nicola S Pocock
Journal:  BMJ Open       Date:  2021-01-18       Impact factor: 2.692

6.  Genomic epidemiology of tuberculosis in eastern Malaysia: insights for strengthening public health responses.

Authors:  Arnold Bainomugisa; Ella M Meumann; Giri Shan Rajahram; Rick Twee-Hee Ong; Lachlan Coin; Dawn Carmel Paul; Timothy William; Christopher Coulter; Anna P Ralph
Journal:  Microb Genom       Date:  2021-05

7.  Annotated Whole-Genome Shotgun Sequence of Mycobacterium tuberculosis MTBR2/09 Isolated from a Sputum Sample in Malaysia.

Authors:  Rahizan Issa; Valentinus H Seradja; Mohd Khairul Hafizi Abdullah; Hatijah Abdul
Journal:  Genome Announc       Date:  2016-06-23

8.  Epidemiology of tuberculosis in Sabah, Malaysia, 2012-2018.

Authors:  Michelle May D Goroh; Giri Shan Rajahram; Richard Avoi; Christel H A Van Den Boogaard; Timothy William; Anna P Ralph; Christopher Lowbridge
Journal:  Infect Dis Poverty       Date:  2020-08-26       Impact factor: 4.520

9.  Health status, healthcare utilisation, and quality of life among the coastal communities in Sabah: Protocol of a population-based survey.

Authors:  Maznah Dahlui; Amirah Azzeri; Mohd Aizat Zain; Mohd Iqbal Mohd Noor; Hafiz Jaafar; Amy Yee Hui Then; Julia Suhaimi; Fatimah Kari; Lota A Creencia; John Roderick Madarcos; Edgar Jose; Lora E Fleming; Mathew P White; Karyn Morrissey; Kamal Solhaimi Fadzil; Hong Ching Goh
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.